Evidence map›Paper›PMID 36232931›Full record

ArticleInternational journal of molecular sciences2022

TRAIL-R Deficient Mice Are Protected from Neurotoxic Effects of Amyloid-β.

Giulia Di Benedetto, Chiara Burgaletto, Maria Francesca Serapide, Rosario Caltabiano, Antonio Munafò, Carlo Maria Bellanca, Rosaria Di Mauro, Renato Bernardini, Giuseppina Cantarella

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Intranasal AβJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Giulia Di BenedettoSection of Pharmacology, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.ORCID 0000-0001-5060-6244
Chiara BurgalettoSection of Pharmacology, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.ORCID 0000-0002-5517-8223
Maria Francesca SerapideSection of Physiology, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.ORCID 0000-0001-6332-4772
Rosario CaltabianoSection of Anatomic Pathology, Department of Medical and Surgical Sciences and Advanced Technologies "G.F. Ingrassia", University of Catania, 95123 Catania, Italy.ORCID 0000-0001-8591-8010
Antonio MunafòSection of Pharmacology, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.ORCID 0000-0003-1370-2880
Carlo Maria BellancaSection of Pharmacology, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.ORCID 0000-0003-2646-7808
Rosaria Di MauroSection of Pharmacology, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.
Renato BernardiniSection of Pharmacology, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.
Giuseppina CantarellaSection of Pharmacology, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.ORCID 0000-0002-7670-9337
University of Catania · IT

Funding

PRIN from the Italian Ministry of Research. 2017YH3SXK
6 · The paper itself

Abstract

TRAIL, a member of TNF superfamily, is a potent inducer of neuronal death. Neurotoxic effects of TRAIL appear mediated by its death receptor TRAIL-R2/DR5. To assess the role of TRAIL/TRAIL-R2 pathway in AD-related neurodegeneration, we studied the impact of the treatment with amyloid-β (Aβ) upon cell viability and inflammation in TRAIL-R-deficient mice (TRAIL-R

Indexed as

Neurotoxicity SyndromesReceptors, TNF-Related Apoptosis-Inducing LigandTumor Necrosis Factor-alphaAmyloid beta-PeptidesAnimalsCaspasesCyclooxygenase 2Glycogen Synthase Kinase 3 betaInflammationMiceMice, KnockoutProto-Oncogene Proteins c-aktTumor Suppressor Protein p53Amyloid beta-PeptidesCaspasesCyclooxygenase 2Glycogen Synthase Kinase 3 betaProto-Oncogene Proteins c-aktReceptors, TNF-Related Apoptosis-Inducing LigandTnfrsf10b protein, mouseTumor Necrosis Factor-alphaTumor Suppressor Protein p53Alzheimer’s diseaseapoptosisneuroinflammationTRAIL-R2

Identifiers

PMID36232931
PMCPMC9569968
OpenAlexW4303699452

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.